Figures & data
Table 1. Number (%) of patients in analysis, by biologic response modifier and by condition.
Table 2. Baseline characteristics: subcutaneous biologic response modifiers.
Table 3. Baseline characteristics: intravenous biologic response modifiers.
Figure 1. Costs per treated patient relative to etanercept. (A) Etanercept vs other TNF blockers approved for indications within RA, PsO, PsA, and AS. (B) Etanercept vs biologic response modifiers not approved for indications within all four of the conditions studied (RA, PsO, PsA, and AS). RA, rheumatoid arthritis; PsO, plaque psoriasis; PsA, psoriatic arthritis; AS, ankylosing spondylitis.
Table 4. Contribution of index and post-index costs to total cost per treated patient.